

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/50, 33/566		A1	(11) International Publication Number: WO 99/67637
			(43) International Publication Date: 29 December 1999 (29.12.99)
(21) International Application Number: PCT/EP99/04286		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 21 June 1999 (21.06.99)			
(30) Priority Data: 98/08093 25 June 1998 (25.06.98) FR			
(71) Applicant (for all designated States except US): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D-64293 Darmstadt (DE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): RASPE, Eric [BE/BE]; 142, avenue du Château, B-77000 Mouscron (BE). BON-HOMME, Yves [FR/FR]; Le Buclay, 21, avenue de la Paix, F-69260 Charbonnières (FR).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(74) Agent: MERCK PATENT GMBH; Frankfurter Strasse 250, D-64293 Darmstadt (DE).			
(54) Title: USE OF REV-ERB FAMILY OF RECEPTORS IN SCREENING			
(57) Abstract <p>The present invention relates to the use of receptors of the Rev-erb family to screen substances which are useful in the treatment of lipid metabolism dysfunctions associated with apolipoprotein C-III. The invention relates more particularly to screening methods for selecting substances which are useful for the treatment of these dysfunctions. Lastly, the invention relates to the use of the substances thus identified for the preparation of therapeutic compositions which are useful for the treatment of lipid metabolism dysfunctions associated with apolipoprotein C-III. The subject of the present invention is also the use of screening tests for the characterization, justification and claim of the mechanism of action of substances possessing anti-atherosclerotic properties using the Rev-erb receptors and/or the response elements thereof, as well as their effect on apo C-III.</p>			

SCANNED, # 12